Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose‐reduced 3‐weekly docetaxel for metastatic castration‐resistant prostate cancer. Issue 5 (10th January 2018)

• Record Type: Journal Article
• Authors: Hamid, Anis A.; Willson, Kaspar; Vincent, Andrew D.; Tamjid, Babak; Lee, Margaret; Bergin, Alice; Gan, Chun; Campbell, Ainsley; Stewart, Josephine; Pezaro, Carmel; Tran, Ben; Weickhardt, Andrew J.
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 14:Issue 5(2018)
• Page Start: e399
• Page End: e404
• Publication Date: 2018-01-10
• Subjects: castration resistant -- chemotherapy toxicity -- docetaxel -- febrile neutropenia -- metastatic prostate cancer; Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.12840
• Languages: English
• ISSNs: 1743-7555

Abstract

Abstract: Background: Docetaxel is an effective therapy for metastatic castration‐resistant prostate cancer (mCRPC); however, many patients experience febrile neutropenia (FN) and cease treatment early due to toxicity. It is not known whether lower dose (LD) q3‐weekly docetaxel impacts toxicity or efficacy. Methods: Multicenter retrospective study included 166 patients with mCRPC who received q3‐weekly docetaxel between 2010 and 2015. Demographic, disease, chemotherapy (standard dose, SD > 60 mg/m 2 vs LD ≤ 60 mg/m 2 ) and toxicity data were collected. Univariable and multivariable logistic and competing risk regression models evaluated docetaxel‐dose association with FN and early treatment cessation (ETC) due to toxicity. Associations between dose and efficacy end points were also evaluated. Analyses were repeated employing inverse propensity score weights. Results: Patients who received LD docetaxel (28.9%) were older with poorer Eastern Cooperative Oncology Group (ECOG) status. Fifteen percent of patients experienced FN, with a nonsignificant trend to lower incidence in the LD group (multiple adjusted odds ratio [OR] = 0.42; P = 0.21). Neither baseline patient nor prior treatment factors were predictive of FN. ETC due to toxicity occurred in 35%, with risk associated with increasing age, comorbidity count and poorer ECOG. There was no difference between LD and SD with respect to ETC due to toxicity, in unweighted and weighted analyses (LD vs SD, multivariable weighted hazard ratio [HR] = 1.47; P = 0.08). LD was associated with reduced prostate‐specific antigen (PSA) response (50% vs 66.1%, multivariable weighted HR = 0.54; P = 0.03) and overall survival (median 7.9 vs 13.8 months, multivariable weighted HR = 2.19; P < 0.0001). Conclusions: LD docetaxel for mCRPC did not mitigate the risk of FN or ETC due to toxicity. Dose reduction may result in poorer PSA response and survival.